153 related articles for article (PubMed ID: 25821166)
1. Safety and feasibility of S-1 adjuvant chemotherapy for pancreatic cancer in elderly patients.
Aoyama T; Katayama Y; Murakawa M; Atsumi Y; Yamaoku K; Kanazawa A; Higuchi A; Shiozawa M; Kobayashi S; Ueno M; Morimoto M; Yamamoto N; Oshima T; Yoshikawa T; Rino Y; Masuda M; Morinaga S
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1115-20. PubMed ID: 25821166
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancer.
Aoyama T; Katayama Y; Murakawa M; Asari M; Kanazawa A; Higuchi A; Shiozawa M; Kobayashi S; Ueno M; Morimoto M; Ohkawa S; Akaike M; Yamamoto N; Yoshikawa T; Rino Y; Masuda M; Morinaga S
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1235-40. PubMed ID: 25297990
[TBL] [Abstract][Full Text] [Related]
3. Safety and feasibility of S-1 adjuvant chemotherapy for gastric cancer in elderly patients.
Aoyama T; Yoshikawa T; Watanabe T; Hayashi T; Ogata T; Cho H; Tsuburaya A
Gastric Cancer; 2012 Jan; 15(1):76-82. PubMed ID: 21717091
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma.
Shinkawa H; Uenishi T; Takemura S; Sakata C; Urata Y; Nozawa A; Hamano G; Kinoshita M; Kubo S
Hepatogastroenterology; 2015; 62(137):169-74. PubMed ID: 25911890
[TBL] [Abstract][Full Text] [Related]
5. Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer.
Jeong JH; Ryu MH; Ryoo BY; Lee SS; Park I; Lee SH; Kim KC; Yook JH; Oh ST; Kim BS; Kang YK
Cancer Chemother Pharmacol; 2012 Oct; 70(4):523-9. PubMed ID: 22864947
[TBL] [Abstract][Full Text] [Related]
6. Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil and oteracil potassium) for colorectal cancer.
Kawahara H; Watanabe K; Ushigome T; Noaki R; Kobayashi S; Yanaga K
Hepatogastroenterology; 2012; 59(113):134-7. PubMed ID: 22251528
[TBL] [Abstract][Full Text] [Related]
7. High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1.
Hayashi K; Imaizumi T; Uchida K; Kuramochi H; Takasaki K
Oncol Rep; 2002; 9(6):1355-61. PubMed ID: 12375048
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors.
Yeo W; Lam KO; Law AL; Lee CC; Chiang CL; Au KH; Mo FK; So TH; Lam KC; Ng WT; Li L
Hong Kong Med J; 2017 Feb; 23(1):54-62. PubMed ID: 27966431
[TBL] [Abstract][Full Text] [Related]
9. Phase II clinical study of alternate-day oral therapy with S-1 as first-line chemotherapy for locally advanced and metastatic pancreatic cancer.
Yamaue H; Satoi S; Kanbe T; Miyazawa M; Tani M; Kawai M; Hirono S; Okada K; Yanagimoto H; Kwon AH; Mukouyama T; Tsunoda H; Chijiiwa K; Ohuchida J; Kato J; Ueda K; Yamaguchi T; Egawa S; Hayashi K; Shirasaka T
Cancer Chemother Pharmacol; 2014 Jan; 73(1):97-102. PubMed ID: 24146260
[TBL] [Abstract][Full Text] [Related]
10. A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine S-1 for non-small-cell lung cancer: high completion and survival rates.
Tsuchiya T; Nagayasu T; Yamasaki N; Matsumoto K; Miyazaki T; Tagawa T; Nakamura A; Minami H; Taniguchi H; Akamine S; Hisano H; Taniguchi Y
Clin Lung Cancer; 2012 Nov; 13(6):464-9. PubMed ID: 22424872
[TBL] [Abstract][Full Text] [Related]
11. [Alternate-day oral therapy with S-1 for adjuvant chemotherapy of gastric cancer].
Takebayashi K; Kawai Y; Tagi T; Matsumura M; Shimizu K; Yamamoto H; Mekata E; Tani T; Sato M
Gan To Kagaku Ryoho; 2012 Mar; 39(3):385-7. PubMed ID: 22421764
[TBL] [Abstract][Full Text] [Related]
12. Clinical implication of peritoneal cytology in the pancreatic cancer patients who underwent curative resection followed by adjuvant gemcitabine or S-1 chemotherapy.
Aoyama T; Katayama Y; Murakawa M; Shiozawa M; Morimoto M; Yamamoto N; Yoshikawa T; Rino Y; Masuda M; Morinaga S
Hepatogastroenterology; 2015; 62(137):200-6. PubMed ID: 25911897
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.
Sudo K; Yamaguchi T; Ishihara T; Nakamura K; Shirai Y; Nakagawa A; Kawakami H; Uno T; Ito H; Saisho H
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):219-24. PubMed ID: 17189072
[TBL] [Abstract][Full Text] [Related]
14. A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer.
Ikeda M; Ioka T; Ito Y; Yonemoto N; Nagase M; Yamao K; Miyakawa H; Ishii H; Furuse J; Sato K; Sato T; Okusaka T
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):163-9. PubMed ID: 22677367
[TBL] [Abstract][Full Text] [Related]
15. [S-1 monotherapy for pancreatic cancer].
Okusaka T; Ueno H; Ikeda M; Morizane C
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():207-12. PubMed ID: 16898004
[TBL] [Abstract][Full Text] [Related]
16. Adherence and feasibility of 2 treatment schedules of S-1 as adjuvant chemotherapy for patients with completely resected advanced lung cancer: a multicenter randomized controlled trial.
Hata Y; Kiribayashi T; Kishi K; Nagashima M; Nakayama T; Ikeda S; Kadokura M; Ozeki Y; Otsuka H; Murakami Y; Takagi K; Iyoda A
BMC Cancer; 2017 Aug; 17(1):581. PubMed ID: 28851314
[TBL] [Abstract][Full Text] [Related]
17. Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer.
Namikawa T; Munekage E; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
Anticancer Res; 2014 Dec; 34(12):7297-301. PubMed ID: 25503163
[TBL] [Abstract][Full Text] [Related]
18. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer.
Aoyama T; Yoshikawa T; Shirai J; Hayashi T; Yamada T; Tsuchida K; Hasegawa S; Cho H; Yukawa N; Oshima T; Rino Y; Masuda M; Tsuburaya A
Ann Surg Oncol; 2013 Jun; 20(6):2000-6. PubMed ID: 23242818
[TBL] [Abstract][Full Text] [Related]
19. [Examination of s-1 therapy for adjuvant chemotherapy in patients with advanced gastric cancer].
Matsui K; Nashimoto A; Yabusaki H; Nakagawa S; Nomura T; Takii Y; Tsuchiya Y; Tanaka O
Gan To Kagaku Ryoho; 2009 Jun; 36(6):953-7. PubMed ID: 19542714
[TBL] [Abstract][Full Text] [Related]
20. Feasibility and toxicity of adjuvant chemotherapy using S-1 granules for local advanced squamous cell carcinoma of the head and neck.
Suzuki S; Honda K; Sato T; Yamazaki K; Ishikawa K
J Chemother; 2015 Oct; 27(5):297-300. PubMed ID: 25971448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]